Literature DB >> 19360334

Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer.

Sateesh Kunigal1, Sajani S Lakka, Prasanna Kumar Sodadasu, Norman Estes, Jasti S Rao.   

Abstract

Stat3, a member of the signal transducer and activator of transcription family, has the potential to mediate cell survival, growth and differentiation. Stat3 is constitutively activated in numerous cancers, including >50% of breast cancers. Previous studies demonstrated that constitutively activated Stat3 plays an important role in breast cancer development and progression by promoting cell proliferation and inhibiting apoptosis. The present study was designed to investigate the potential use of RNA interference (RNAi) to block Stat3 expression and activation, as well as the subsequent effect on human breast cancer cell growth. Our studies show that knockdown of STAT3 expression by siRNA reduced expression of Bcl-xL and survivin in MDA-MB-231 cells, and also led to Fas mediated intrinsic apoptotic pathway by activating caspases -8, -9, -3 and PARP1 cleavage. In nude mice, pRNAi-Stat3 significantly suppressed tumor growth compared with controls. It also suppressed Stat3 expression, and downregulated BcL-xL and upregulated Fas, Fas-L and cleaved caspase-3 expression within the tumor, which significantly induced apoptosis and led to tumor suppression. Thus, targeting Stat3 signaling using siRNA may serve as a novel therapeutic strategy for the treatment of breast cancers expressing constitutively activated Stat3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360334      PMCID: PMC2668130     

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  49 in total

1.  Specificity of short interfering RNA determined through gene expression signatures.

Authors:  Dimitri Semizarov; Leigh Frost; Aparna Sarthy; Paul Kroeger; Donald N Halbert; Stephen W Fesik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

Review 2.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 3.  Apoptotic signaling pathways: caspases and stress-activated protein kinases.

Authors:  Ssang-Goo Cho; Eui-Ju Choi
Journal:  J Biochem Mol Biol       Date:  2002-01-31

4.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

5.  BCL2 antisense reduces prostate cancer cell survival following irradiation.

Authors:  Susan L Scott; Roger Higdon; Laurel Beckett; Xu-Bao Shi; Ralph W deVere White; John D Earle; Paul H Gumerlock
Journal:  Cancer Biother Radiopharm       Date:  2002-12       Impact factor: 3.099

6.  Diarylurea compounds inhibit caspase activation by preventing the formation of the active 700-kilodalton apoptosome complex.

Authors:  Ulrik Lademann; Kelvin Cain; Mads Gyrd-Hansen; David Brown; Dan Peters; Marja Jäättelä
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

7.  RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells.

Authors:  Soo Ok Lee; Wei Lou; Khusroo M Qureshi; Farideh Mehraein-Ghomi; Donald L Trump; Allen C Gao
Journal:  Prostate       Date:  2004-09-01       Impact factor: 4.104

8.  Fas and Fas-associated death domain protein regulate monocyte chemoattractant protein-1 expression by human smooth muscle cells through caspase- and calpain-dependent release of interleukin-1alpha.

Authors:  Friedemann J Schaub; W Conrad Liles; Nicola Ferri; Kirsten Sayson; Ronald A Seifert; Daniel F Bowen-Pope
Journal:  Circ Res       Date:  2003-08-28       Impact factor: 17.367

9.  Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.

Authors:  Nianyu Li; Kathy Ragheb; Gretchen Lawler; Jennie Sturgis; Bartek Rajwa; J Andres Melendez; J Paul Robinson
Journal:  J Biol Chem       Date:  2002-12-20       Impact factor: 5.157

10.  Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells.

Authors:  Liza Konnikova; Maciej Kotecki; Mathew M Kruger; Brent H Cochran
Journal:  BMC Cancer       Date:  2003-09-17       Impact factor: 4.430

View more
  24 in total

1.  STAT3 promotes the proliferation and migration of hepatocellular carcinoma cells by regulating AKT2.

Authors:  Yi Xie; Jianmin Li; Chao Zhang
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

2.  STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer.

Authors:  Hanan Armanious; Pascal Gelebart; John Mackey; Yupo Ma; Raymond Lai
Journal:  Int J Clin Exp Pathol       Date:  2010-07-25

3.  Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.

Authors:  Samaresh Sau; Sujan Kumar Mondal; Sushil K Kashaw; Arun K Iyer; Rajkumar Banerjee
Journal:  Mol Cell Biochem       Date:  2017-06-05       Impact factor: 3.396

4.  Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.

Authors:  Jee-Eun Kim; Dong-Hoon Jin; Wang Jae Lee; Daeyoung Hur; T-C Wu; Daejin Kim
Journal:  Pharmacol Res       Date:  2013-02-18       Impact factor: 7.658

Review 5.  Constitutive activation of STAT3 in breast cancer cells: A review.

Authors:  Kasturi Banerjee; Haluk Resat
Journal:  Int J Cancer       Date:  2015-11-28       Impact factor: 7.396

Review 6.  Nucleic acid-based approaches to STAT inhibition.

Authors:  Malabika Sen; Jennifer R Grandis
Journal:  JAKSTAT       Date:  2012-10-01

7.  Apoptosis induced by knockdown of uPAR and MMP-9 is mediated by inactivation of EGFR/STAT3 signaling in medulloblastoma.

Authors:  Ramaprasada Rao Kotipatruni; Arun Kumar Nalla; Swapna Asuthkar; Christopher S Gondi; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

Review 8.  STAT inhibitors for cancer therapy.

Authors:  Muhammad Furqan; Akintunde Akinleye; Nikhil Mukhi; Varun Mittal; Yamei Chen; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-12-05       Impact factor: 17.388

9.  Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.

Authors:  Ailian Xiong; Zhengduo Yang; Yicheng Shen; Jia Zhou; Qiang Shen
Journal:  Cancers (Basel)       Date:  2014-04-16       Impact factor: 6.639

10.  STAT3 in Cancer-Friend or Foe?

Authors:  Hai-Feng Zhang; Raymond Lai
Journal:  Cancers (Basel)       Date:  2014-07-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.